Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research
14 Dezembro 2023 - 10:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the
publication of a special issue of Cancers journal entirely
dedicated to the Company’s optical genome mapping (OGM) workflow.
The issue, which features guest editors Dr. Adam Smith from
University of Toronto, Dr. Gordana Raca from Children’s Hospital
Los Angeles, and Dr. Alexander Hoischen from Radboud University
Medical Center, includes eight peer-reviewed publications, with
three additional publications expected to come, covering the use of
OGM in hematological malignancy research and demonstrating its
potential to offer significant research insights in a simple and
effective workflow.
In an editorial, Drs. Smith, Raca and Hoischen describe the
advantages OGM has over traditional cytogenetic methods of
analysis, including karyotyping (KT), fluorescence in situ
hybridization (FISH), and chromosomal microarray analysis (CMA),
such as higher resolution and the ability to detect impactful
structural variants (SVs). The guest editors also discuss
limitations of long and short-read sequencing for SV detection,
including challenges with resolution, sensitivity, throughput,
achieved coverage, and price per genome. The guest editors note
that OGM offers benefits for laboratory adoption, due to its
cost-efficient and easily scalable workflow and simple analysis
pipeline and software system. They conclude that OGM could
enable “next generation cytogenetics” due to its potential to
replace traditional cytogenetic methods and detect variants that
may increase the understanding of hematologic malignancies and
further expand hematological research.
The issue’s other publications, authored by researchers from the
United States, Canada, Germany, Finland, and a consortium of
Spanish laboratories, cover research indications including acute
myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myeloma
and myeloid cancers. These publications include findings that
demonstrate OGM’s high level of concordance with traditional
methods for the detection of SVs, ability to identify additional
pathogenic SVs missed by those methods, contributions to
comprehensive tumor profiling, and potential to influence disease
classification and risk prognostication.
“I personally believe the importance of OGM for hematological
malignancies research cannot be overstated. What I have seen
over my career as a molecular cytogeneticist is that oncologists
need more information. The papers published in this dedicated
issue elegantly illustrate how information provided by OGM
surpasses the capabilities of the current tools in cancer research.
I want to congratulate the co-editors on creating such an
impactful compilation of important research results and original
papers,” commented Alka Chaubey, PhD, FACMG, chief medical officer
of Bionano.
“This special edition of Cancers dedicated to OGM is a
significant milestone for the technique and for people in the
various fields of genome analysis who are looking for ways to move
the community forward. We were pleased to see the guest
editors and publication authors share findings that underscore
OGM’s potential to replace traditional cytogenetic methods and show
that OGM offers significant benefits that sequencing can’t offer.
We agree with the editors’ note that OGM is a powerful tool in the
cytogenetics repertoire that may contribute to the growth and
relevance of the field,” stated Erik Holmlin, PhD, president
and chief executive officer of Bionano.
The publication can be found here.
About BionanoBionano is a provider of genome
analysis solutions that can enable researchers and clinicians to
reveal answers to challenging questions in biology and medicine.
The Company’s mission is to transform the way the world sees the
genome through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen,
Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. The Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. The
Company additionally offers nucleic acid extraction and
purification solutions using proprietary isotachophoresis
technology. For more information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of
BionanoThis press release contains forward-looking
statements contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Words such
as “believe,” “can,” “could,” “may,” “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances and the negatives
thereof) convey uncertainty of future events or outcomes and are
intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the ability and
utility of OGM to detect SVs relevant to hematologic malignancies
and hematological research; the potential of OGM to detect SVs
compared to traditional cytogenetic techniques and long- and
short-read sequencing; the potential of OGM to offer benefits for
laboratory adoption; and other statements that are not historical
facts. Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and future bank
failures, the ongoing Ukraine-Russia conflict, related sanctions,
the Israel-Hamas war, and any global pandemics, on our business and
the global economy; challenges inherent in developing,
manufacturing and commercializing products; our ability to further
deploy new products and applications and expand the markets for our
technology platforms; failure of OGM to detect SVs relevant to
hematologic malignancies and hematological research; failure of OGM
to detect SVs compared to traditional cytogenetic techniques and
long- and short-read sequencing; failure of OGM to offer benefits
for laboratory adoption; future publications that contradict or do
not support the statements in the special issue of Cancers; our
expectations and beliefs regarding future growth of the business
and the markets in which we operate; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts and our
ability to continue as a “going concern”; and including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2022 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We are under no duty to update any of these
forward-looking statements after the date they are made to conform
these statements to actual results or revised expectations, except
as required by law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date the statements are made. Moreover, except as
required by law, neither we nor any other person assumes
responsibility for the accuracy and completeness of the
forward-looking statements contained in this press release.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024